Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 404-412

  Wang, Shihua ^a   Wu, Jiansheng ^a   Suburu, Janel ^a   Gu, Zhennan ^a   Cai, Jiaozhong ^a   Axanova, Linara S ^a   Cramer, Scott D ^a   Thomas, Michael J ^a   Perry, Donna L ^a   Edwards, Iris J ^a   Mucci, Lorelei A ^b   Sinnott, Jennifer A ^b   Loda, Massimo F ^c   Sui, Guangchao ^a   Berquin, Isabelle M ^a   Chen, Yong Q ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PRASTERONE; PROTEASOME; PROTEIN KINASE B; RNA; TESTOSTERONE;

ALLOGRAFT; ANDROGEN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; GENE DELETION; GENE EXPRESSION REGULATION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TESTOSTERONE BLOOD LEVEL; TISSUE MICROARRAY; TUMOR XENOGRAFT;

EID: 84863047452     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr290     Document Type: Article

References (37)

1. Maehama, T. et al. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273, 13375-13378.
2. Gray, I.C. et al. (1998) Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer, 78, 1296-1300.
3. Whang, Y.E. et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad. Sci. U S A, 95, 5246-5250.
4. McCall, P. et al. (2008) Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br. J. Cancer, 99, 1296-1301.
5. Suzuki, H. et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res., 58, 204-209.
6. Vlietstra, R.J. et al. (1998) Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res., 58, 2720-2723.
7. Yoshimoto, M. et al. (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer, 97, 678-685.
8. McMenamin, M.E. et al. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59, 4291-4296.
9. Wang, S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads tometastatic prostate cancer. Cancer Cell, 4, 209-221.
10. Crawford, E.D. et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321, 419-424.
11. Eisenberger, M.A. et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med., 339, 1036-1042.
12. Shen, M.M. et al. (2007) Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res., 67, 6535-6538.
13. Jiao, J. et al. (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res., 67, 6083-6091.
14. Chen, Y.Q. et al. (2007) Dietary fat-gene interactions in cancer. Cancer Metastasis Rev., 26, 535-551.
15. Norrish, A.E. et al. (1999) Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br. J. Cancer, 81, 1238-1242.
16. Terry, P. et al. (2001) Fatty fish consumption and risk of prostate cancer. Lancet, 357, 1764-1766.
17. Yang, Y.J. et al. (1999) Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin. Biochem., 32, 405-409.
18. Augustsson, K. et al. (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 64-67.
19. Berquin, I.M. et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest., 117, 1866-1875.
20. Barclay, W.W. et al. (2005) Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate, 63, 291-298.
21. Barclay, W.W. et al. (2008) Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells, 26, 600-610.
22. Pfeifer, A. et al. (2001) Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc. Natl Acad. Sci. U S A, 98, 11450-11455.
23. Deng, Z. et al. (2009) Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene, 28, 3746-3757.
24. Nelson, J.F. et al. (1975) Plasma testosterone levels in C57BL/6J male mice: effects of age and disease. Acta. Endocrinol. (Copenh), 80, 744-752.
25. Berquin, I.M. et al. (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett., 269, 363-377.
26. McEntee, M.F. et al. (2008) Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am. J. Pathol., 173, 229-241.
27. Ammirante, M. et al. (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 464, 302-305.
28. de Vere White, R. et al. (1997) Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol., 31, 1-6.
29. Gregory, C.W. et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res., 61, 4315-4319.
30. Brown, R.S. et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol., 198, 237-244.
31. Visakorpi, T. et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9, 401-406.
32. Koivisto, P. et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57, 314-319.
33. Wallen, M.J. et al. (1999) Androgen receptor gene mutations in hormone-refractory prostate cancer. J. Pathol., 189, 559-563.
34. Linja, M.J. et al. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61, 3550-3555.
35. Chung, B.H. et al. (2001) Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis, 22, 1201-1206.
36. Mulholland, D.J. et al. (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell, 19, 792-804.
37. Weiss, L.A. et al. (2005) Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo Study. Am. J. Clin. Nutr., 81, 934-938.